Search
ChatPaper
AI Writing
analysis
Analysis
编组
Open Data
more
More
RankingsMust ReadingJournal&ConferenceAI TRAI HistoryMaster Reading TreeXiaomai's Star TalentsTrajectoryTalentNDI TrackerOpenAI sign Language
VIPCreated with Sketch.

Orally Bioavailable Macrocyclic Peptide That Inhibits Binding of PCSK9 to the Low Density Lipoprotein Receptor.

Douglas G Johns,Louis-Charles Campeau,Puja Banka,An Bautmans,Tjerk Bueters,Elisabetta Bianchi,Danila Branca,Paul G Bulger, Inne Crevecoeur,Fa-Xiang Ding,Robert M Garbaccio,Erik D Guetschow, Yan Guo,Sookhee N Ha,Jennifer M Johnston,Hubert Josien,Eunkyung A Kauh,Kenneth A Koeplinger,Jeffrey T Kuethe,Eseng Lai, Christine L Lanning,Anita Y H Lee,Li Li, Anilkumar G Nair,Edward A O'Neill,S Aubrey Stoch,David A Thaisrivongs,Thomas J Tucker,Petr Vachal,Kristien van Dyck,Frederic P Vanhoutte,Bram Volckaert,Dennis G Wolford, Andy Xu,Tian Zhao, Dan Zhou,Susan Zhou,Xiaohong Zhu,Hratch J Zokian,Abbas Walji,Harold B Wood

Circulation（2023）

Cited 9|Views27
No score
Abstract
This work validates the use of mRNA display technology for identification of novel oral therapeutic agents, exemplified by the identification of an oral PCSK9 inhibitor, which has the potential to be a highly effective cholesterol lowering therapy for patients in need.
More
Translated text
Key words
bioavailable macrocyclic peptide,low density lipoprotein receptor,pcsk9
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined